Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation

References

• Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019; 380(15):1450–62. doi:https://doi.org/10.1056/NEJMra1713263.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:https://doi.org/10.3322/caac.21166.
   PubMed Web of Science ®Google Scholar
• Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl. 2011;17(Suppl 2):S6–S13. doi:https://doi.org/10.1002/lt.22423.
   PubMedGoogle Scholar
• Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50. doi:https://doi.org/10.1002/hep.29913.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address EEE, European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:https://doi.org/10.1016/j.jhep.2018.03.019.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:https://doi.org/10.1016/j.ctrv.2018.11.002.
   PubMed Web of Science ®Google Scholar
• Peng Z-W, Zhang Y-J, Chen M-S, Xu L, Liang H-H, Lin X-J, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31(4):426–32. doi:https://doi.org/10.1200/JCO.2012.42.9936.
   PubMed Web of Science ®Google Scholar
• Wang W-D, Zhang L-H, Ni J-Y, Jiang X-Y, Chen D, Chen Y-T, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma within the Milan criteria: a meta-analysis. Korean J Radiol. 2018;19(4):613–22. doi:https://doi.org/10.3348/kjr.2018.19.4.613.
   PubMed Web of Science ®Google Scholar
• Gui CH, Baey S, D'Cruz RT, Shelat VG. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma – a meta-analysis. Eur J Surg Oncol. 2020;46(5):763–71. doi:https://doi.org/10.1016/j.ejso.2020.01.004.
   PubMed Web of Science ®Google Scholar
• Jang JH, Kim DH, Surh YJ. Dynamic roles of inflammasomes in inflammatory tumor microenvironment. NPJ Precis Oncol. 2021;5(1):18. doi:https://doi.org/10.1038/s41698-021-00154-7.
   PubMed Web of Science ®Google Scholar
• Sylman JL, Mitrugno A, Atallah M, Tormoen GW, Shatzel JJ, Tassi Yunga S, et al. The predictive value of inflammation-related peripheral blood measurements in cancer staging and prognosis. Front Oncol. 2018;8:78. doi:https://doi.org/10.3389/fonc.2018.00078.
   PubMed Web of Science ®Google Scholar
• Li S, Guo JH, Lu J, Wang C, Wang H. Prognostic value of preoperative prognostic nutritional index and body mass index combination in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. CMAR. 2021;13:1637–50. doi:https://doi.org/10.2147/CMAR.S290983.
   Google Scholar
• Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology. 2012;262(2):689–700. doi:https://doi.org/10.1148/radiol.11110637.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology. 2014;273(1):241–60. doi:https://doi.org/10.1148/radiol.14132958.
   PubMed Web of Science ®Google Scholar
• Jeong SW. Neutrophil-to-lymphocyte ratio as a prognostic biomarker in hepatocellular carcinoma after transarterial chemoembolization. Ann Transl Med. 2020;8(18):1124 doi:https://doi.org/10.21037/atm-20-4296.
   PubMed Web of Science ®Google Scholar
• Liao W, Zhang J, Zhu Q, Qin L, Yao W, Lei B, et al. Preoperative neutrophil-to-lymphocyte ratio as a new prognostic marker in hepatocellular carcinoma after curative resection. Transl Oncol. 2014;7(2):248–55. doi:https://doi.org/10.1016/j.tranon.2014.02.011.
   PubMed Web of Science ®Google Scholar
• Terashima T, Yamashita T, Iida N, Yamashita T, Nakagawa H, Arai K, et al. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res. 2015;45(9):949–59. doi:https://doi.org/10.1111/hepr.12436.
   PubMed Web of Science ®Google Scholar
• Chu MO, Shen C-H, Chang T-S, Xu H-W, Yen C-W, Lu S-N, et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation. Sci Rep. 2018;8(1):16611 doi:https://doi.org/10.1038/s41598-018-34543-z.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. doi:https://doi.org/10.1016/j.cell.2010.01.025.
   PubMed Web of Science ®Google Scholar
• Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, et al. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13(1):78. doi:https://doi.org/10.1186/1471-2407-13-78.
   PubMedGoogle Scholar
• Chu HH, Kim JH, Shim JH, Gwon DI, Ko H-K, Shin JH, et al. Neutrophil-to-lymphocyte ratio as a biomarker predicting overall survival after chemoembolization for intermediate-stage hepatocellular carcinoma. Cancers (Basel). 2021;13(11)2830. doi:https://doi.org/10.3390/cancers1311:.
   PubMed Web of Science ®Google Scholar
• Shelat VG. Role of inflammatory indices in management of hepatocellular carcinoma-neutrophil to lymphocyte ratio. Ann Transl Med. 2020;8(15):912 doi:https://doi.org/10.21037/atm-2020-90.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu Z, Peng Y, Li D, Jiang Y, Pan F, et al. Correlationship between Ki67, VEGF, and p53 and hepatocellular carcinoma recurrence in liver transplant patients. Biomed Res Int. 2021;2021:6651397 doi:https://doi.org/10.1155/2021/6651397.
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4):283–7. doi:https://doi.org/10.1023/B:AGEN.0000029415.62384.ba.
   PubMedGoogle Scholar
• Hsieh M-C, Hsu H-T, Hsiao P-C, Yang S-F, Yeh C-B, Bien M-Y, et al. Role of VEGF-C gene polymorphisms in susceptibility to hepatocellular carcinoma and its pathological development. J Clin Lab Anal. 2014;28(3):237–44. doi:https://doi.org/10.1002/jcla.21672.
   PubMed Web of Science ®Google Scholar
• Liu ZL, Zhu LL, Liu JH, Pu ZY, Ruan ZP, Chen J. Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma. Aging (Albany NY)). 2020;12(24):25172–88. doi:https://doi.org/10.18632/aging.104119.
   PubMedGoogle Scholar
• Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010;138(5):1931–42. doi:https://doi.org/10.1053/j.gastro.2009.12.051.
   PubMed Web of Science ®Google Scholar
• Hickey RM, Kulik LM, Nimeiri H, Kalyan A, Kircher S, Desai K, et al. Immuno-oncology and its opportunities for interventional radiologists: immune checkpoint inhibition and potential synergies with interventional oncology procedures. J Vasc Interv Radiol. 2017;28(11):1487–94. doi:https://doi.org/10.1016/j.jvir.2017.07.018.
   PubMed Web of Science ®Google Scholar
• Song G, Shi Y, Zhang M, Goswami S, Afridi S, Meng L, et al. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. Cell Discov. 2020;6(1):90 doi:https://doi.org/10.1038/s41421-020-00214-5.
   PubMed Web of Science ®Google Scholar
• Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells. 2020;9(5) :1299. doi:https://doi.org/10.3390/cells905.
   Web of Science ®Google Scholar
• Cheng N, Bai X, Shu Y, Ahmad O, Shen P. Targeting tumor-associated macrophages as an antitumor strategy. Biochem Pharmacol. 2021;183:114354 doi:https://doi.org/10.1016/j.bcp.2020.114354.
   PubMed Web of Science ®Google Scholar
• Tajiri K, Baba H, Kawai K, Minemura M, Yasumura S, Takahara T, et al. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. J Gastroenterol Hepatol. 2016;31(7):1291–9. doi:https://doi.org/10.1111/jgh.13287.
   PubMed Web of Science ®Google Scholar